19829-38-0

Upstream product

• 100-39-0 benzyl bromide 
• 614-75-5 2-Hydroxyphenylacetic acid 
• 108-20-3 di-isopropyl ether 
• 104-15-4 toluene-4-sulfonic acid 
• 70340-04-4 (2-hydroxybenzyl)triphenylphosphonium bromide 
• 501-53-1 benzyl chloroformate 
• 22446-37-3 methyl (2-hydroxyphenyl)acetate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 787619-56-1 [2-(2-Diethylaminoethoxy)phenyl]acetic acid benzyl ester 
• 787619-57-2 [2-(2-morpholin-4-yl-ethoxy)-phenyl]-acetic acid benzyl ester 
• 1191257-51-8 (3R,4S,Z)-benzyl 2-benzylidene-3-phenylchroman-4-carboxylate 
• 787620-76-2 [2-(2-morpholin-4-yl-ethoxy)-phenyl]-acetic acid 

Relevant academic research and scientific papers

AROMATIC SULFONAMIDE DERIVATIVES

Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a

Src homology 2 (SH2) domains play a central role in signal transduction. Although many SH2 domains have been validated as drug targets, their structural similarity makes development of specific inhibitors difficult. The cancer-relevant transcription facto

NOVEL COMPOUNDS AND THEIR USE IN THERAPY

The invention provides compounds which inhibit N-myristoyltransferase and are selective for protozoal N-myristoyltransferase and, consequently suitable to treat microbial infections, including viral and fungal infections, and protozoan infections such as malaria, leishmaniasis and sleeping sickness.

The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents

Starting from a non-selective pyrazolo-pyrimidone lead, the sequential use of parallel medicinal chemistry and directed synthesis led to the discovery of potent, highly selective, and orally bioavailable PDE9 inhibitors. The availability of these tools allowed for a thorough evaluation of the therapeutic potential of PDE9 inhibition.

PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease

The invention provides compounds of Formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein A, P, J, x, and R10 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including, diabetes, including type 1 and type 2 diabetes, hyperglycemia, dyslipidemia, impaired glucose tolerance, metabolic syndrome, and/or cardiovascular disease.

Perhydroisoindole derivatives and pharmaceutical compositions containing them

This invention relates to derivatives of perhydroisoindol of formula: STR1 in which the radicals R are hydrogen atoms or together form a bond, the symbols R' are phenyl radicals which can be substituted by a halogen atom or a methyl radical in position 2 or 3, X is an oxygen atom or an NH radical, R1 is optionally substituted phenyl, or cyclohexadienyl, naphthyl, or heterocyclyl, R2 is H, halogen, OH, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkyloxy, alkylthio, acyloxy, carboxy, optionally substituted alkyloxycarbonyl, benzyloxycarbonyl, amino or acylamino, R3 is halogen or OH and R4 is H or halogen if R3 is halogen, in their isomer forms, or mixture thereof, and possibly also their salts when they exist, and preparation thereof. The derivatives of the invention are particularly interesting as P substance antagonist.